Page last updated: 2024-12-11

trans-2-en-valproate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-propyl-2-pentenoic acid: valproate metabolite; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6437068
CHEMBL ID117487
CHEBI ID80639
SCHEMBL ID1003142
MeSH IDM0062490

Synonyms (54)

Synonym
69827-64-1
trans-2-ene-valproic acid
delta-2(e)-valproate
valeric acid, 2-propylidene-, (e)-
e-2-en-valproic acid
2-pentenoic acid, 2-propyl-, (e)-
trans-2-propyl-2-pentenoic acid
(e)-2-en-vpa
(2e)-2-propyl-2-pentenoic acid
60218-41-9
2-ene-vpa
2-n-propyl-2-pentenoic acid
trans-2-en-vpa
2-propyl-2-pentenoic acid
2-en-valproic acid
e-delta(2)-valproic acid
delta2,3 vpe
trans-2-en-valproate
2-n-propylpent-2-enoic acid
2-pentenoic acid, 2-propyl-
delta2-valproic acid
(e)-2-ene-valproic acid
2-ene-valproate
chebi:80639 ,
CHEMBL117487
2-propylpenten-2-oic acid
2-propyl-2-pentenoate
(e,z) 2-propyl-2-pentenoic acid
(e)-2-propylpent-2-enoic acid
unii-6w67l10m6t
6w67l10m6t ,
33786-47-9
2-propyl-2-pentenoic acid, (2e)-
2-pentenoic acid, 2-propyl-, (2e)-
valproic acid, trans-2-ene
2-propyl-(e)-2-pentenoic acid
2-propyl-2(e)-pentenoic acid
BRD-K17219111-001-01-6
SCHEMBL1003142
2-enevalproicacid
e-2-propyl-2-pentenoic acid
2-pentenoicacid,2-propyl-,(2e)-
(2e)-2-propylpent-2-enoic acid
2-ene-valproic acid
LMFA01030968
2-propyl-2-pentenoic acid, analytical standard
mfcd00801107
AKOS030525216
AS-60440
(e,z)-2-propyl-2-pentenoic acid
Q27149689
DTXSID001306621
CS-0363052
(e)-2-propylpent-2-enoicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our results indicate that all three risk factors clearly increase the metabolic conversion of VPA to 4-en, the most toxic VPA metabolite, and that polytherapy and high VPA serum level result in the inhibited beta-oxidative metabolism of VPA to 2-en."( Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
Fukushima, Y; Hirano, T; Ishida, M; Kaneko, S; Koide, N; Kondo, T; Muranaka, H; Otani, K; Yokoyama, M,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were determined."( Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers.
Düsing, RH, 1992
)
0.28
" Removal of the implanted pumps and measurement of the decay of the drug levels revealed that the half-life of the main plasma metabolite 2-en(2-propyl-2-pentenoic acid) exceeded that of VPA."( Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.
Nau, H; Zierer, R,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" In monopharmacy patients, plasma NH3 levels did not depend on age, VPA dosage or serum levels."( Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Fukushima, Y; Hirano, T; Ishida, M; Kaneko, S; Koide, N; Kondo, T; Muranaka, H; Nakata, S; Otani, K; Yokoyama, M,
)
0.13
" Because of the rapid conversion of the prodrugs to the parent drug, levels of VPA in plasma after administration of the prodrugs peaked at 6-26 min after dosing and did not yield an in vivo sustained-release dosage profile."( Pharmacokinetic analysis of ester prodrugs of valproic acid.
Bialer, M; Hadad, S; van der Kleijn, E; Vree, TB, 1992
)
0.28
" Urine was collected for one dosage interval (12 h) at steady state for each dose and assayed for 15 VPA metabolites by gas chromatography/mass spectrometry (GCMS)."( Effect of valproate dose on formation of hepatotoxic metabolites.
Acheampong, AA; Anderson, GD; Levy, RH; Wilensky, AJ,
)
0.13
" To assess potential use of E-delta 2-VPA as an alternate to VPA, a dose-response study comparing the anticonvulsant activity and neurotoxicity of E-delta 2-VPA and VPA was conducted in rats using the intravenous (i."( Comparative pharmacodynamics and brain distribution of E-delta 2-valproate and valproate in rats.
Semmes, RL; Shen, DD,
)
0.13
" This result has to be taken into account when dose-response relationships are evaluated."( Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
Klug, S; Lewandowski, C; Nau, H; Neubert, D, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methyl-branched fatty acidAny branched-chain fatty acid containing methyl branches only.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Valproic Acid Metabolism Pathway1132

Bioassays (10)

Assay IDTitleYearJournalArticle
AID299650Increase in protein disulfide isomerase level in HEK293 cells at 2 mM by immunoblot2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID299646Increase in GRP78 protein level in HEK293 cells at 2 mM by immunoblot2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID243251Inhibitory activity against Glycogen synthase kinase-3 beta, expressed as percent control2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID250473Anti-convulsant activity in experimental animal model; ++ = relative to valproate2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID19690Partition coefficient (logP)1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-activity relationships of unsaturated analogues of valproic acid.
AID299653Inhibition of GSK3-beta at 2 mM relative to control2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
AID112364Anticonvulsant activity against mice after intraperitoneal administration1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-activity relationships of unsaturated analogues of valproic acid.
AID110434Brain concentration after 15 min of administration1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-activity relationships of unsaturated analogues of valproic acid.
AID243252Inhibitory activity against Glycogen synthase kinase-3 alpha, expressed as percent control2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
AID299645Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 2 mM after 48 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (18.75)18.7374
1990's33 (68.75)18.2507
2000's6 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (94.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]